MedTrace Logo

A Study to Evaluate the Safety and Efficacy of RQC for AMD

NCT05062486 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2025-07-30

No results posted yet for this study

Summary

To evaluate the safety and efficacy of resveratrol, quercetin, and curcumin in combination (RQC) over 2 years in patients with age-related macular degeneration (AMD).

Conditions

  • Age-related Macular Degeneration

Interventions

DRUG

Resveratrol, Quercetin, Curcumin (RQC)

100 mg resveratrol, 120 mg quercetin, 1000 mg curcumin BID

DRUG

Curcumin

1000 mg curcumin BID

Sponsors & Collaborators

  • Paul A Knepper, MD PhD

    lead OTHER

Principal Investigators

  • Paul A Knepper, MD, PhD · Zaparackas Knepper, Ltd

  • Zibute Zaparackas, MD · Zaparackas Knepper, Ltd

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-04
Primary Completion
2024-11-07
Completion
2024-11-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05062486 on ClinicalTrials.gov